AstraZeneca Pharma India Limited has been penalised by the Registrar of Companies (ROC) for delaying the filing of Form MR-2 concerning the appointment of Dr. Sanjeev Kumar Panchal as Managing Director.

The company received the penalty order on September 17, 2026, from the ROC Bengaluru. The adjudication was under Section 454 of the Companies Act, 2013, for violating Section 201 read with Rule 7(3) of the Companies (Appointment and Remuneration) Rules, 2014.

Penalty Details

The order imposes a total financial penalty of ₹2,38,000. The breakdown of the fines is as follows:

Dr. Panchal served as Managing Director from January 1, 2023, to June 30, 2025. The required Form MR-2 was not filed within the prescribed timeline following his appointment in early 2023.

Cause of Delay

The company attributed the filing delay to technical glitches on the Ministry of Corporate Affairs (MCA) portal. Dr. Panchal’s Director Identification Number (DIN) was erroneously marked as inactive due to alleged non-filing of DIR-3 KYC, a requirement the company stated was inapplicable at the time.

The DIN was activated in August 2023 after sustained follow-up efforts. The requisite filings were completed subsequently. The company disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on September 18, 2026.

AstraZeneca Pharma accepted the resignation of Dr. Sandeep Arora as Director – Medical Affairs, effective September 15, 2026. The executive will leave to pursue career opportunities outside the organization.

Dr. Arora served as Director – Medical Affairs for the Biopharmaceutical Business Unit and Rare Disease Business Unit. He completed his handover period and was relieved from duties by the close of business hours on the effective date.

Regulatory Disclosure

The company disclosed the change pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information was submitted to both the BSE Limited and the National Stock Exchange of India Limited.

The filing references SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026, regarding Senior Management Personnel changes. Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure on September 15, 2026.

Succession Plans

AstraZeneca Pharma India Limited stated it is in the process of looking for a suitable replacement for the position. The resignation letter, enclosed as Annexure A, confirmed Dr. Arora’s decision to exit the company.